HUE029946T2 - Anti-CD4 antitest - Google Patents

Anti-CD4 antitest Download PDF

Info

Publication number
HUE029946T2
HUE029946T2 HUE09835062A HUE09835062A HUE029946T2 HU E029946 T2 HUE029946 T2 HU E029946T2 HU E09835062 A HUE09835062 A HU E09835062A HU E09835062 A HUE09835062 A HU E09835062A HU E029946 T2 HUE029946 T2 HU E029946T2
Authority
HU
Hungary
Prior art keywords
antibody
ser
seq
amino acid
leu
Prior art date
Application number
HUE09835062A
Other languages
English (en)
Inventor
Tomoaki Nakagawa
Sayaka Hori
Rinpei Niwa
Tsuguo Kubota
Kazuhiro Masuda
Kazuyasu Nakamura
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of HUE029946T2 publication Critical patent/HUE029946T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (1)

  1. Szab&amp;daln; i igenypootek s. llumán k D~. «ne«* rg§{töIÄä!ii; antitest, mely antuiti Militer IpÂHÈ- ..v„.tíhs.n.űm....x. ) human CP4 táv estiaoedulurs tegnnabv? ketodtk ts * vV - !ekx>,nmnuh\ htmian kniisj mit neat. meKnen az annus? nebéz ianc xanabdis to;2?o?a -, \· î u d 1 i. sKàsnù szekveneíájú amrnosav szekvenciát tartalmazza*:^ 1:l<äPÄissÄv««ek U ·*' ^inesasemak meg Meló szekréciós jd </ck\ oncu kivétek^ ek es m antitest knotty« lane vaitahihe regarni ?VL} a 112. «sàmû szekvenciája antinosav szekvenciái tattalmazza, a 22. szama szekvencia 1 -20. aminosavaimk megfelelő szekréciós jel szekvencia kivételével' vagy lii! s'k> vekombtreuis humanizált antitest. mcHbem (u) az antitest Υ||.μ a 96. számú szekvenciája amippsgy szekvenciái tartalmaim.|fmz antitest "Vk-je a i%, számú szekvenciáiú aminosav ssekvenciákMákááiM; (b) az unities;? VH*ja a 98. számú szekvenciáik amstesl VLje a J8, számú szekvenciám aminosav szekvenciát tartalmasa; W) az antitest YH-ja a 77. vcame seeksenciáiú amhtosax szekvenciát ta; iuíinazzu é\ az mn.;iexi V L*je a »-h, számú szekvenciáit! amirsosav szekvenciát tartalmazza; 1st) az mimes? VH-ja a 109. szstnut azé kv énei áj ú ammosav szekvenciái tartalmazza es ez. an; nest V, I tea g v ,,,, ,,c u ^ , > viurx a' sAkvsnuti kuiabmn <-e χ v; |_e}az. antitest VH-ja a 100. számú szekveneiájú aminosav szekvenciát lartaimákza ,is az antitest V L-je a 102. számú szekvenciáiù aminosav szekvenciát tartalmazza. iái k |§enf|Äf^ á!;é! MÄtet: Vli-ja a 96. számú szekven ciám aminosav szekvenciát tartalmazza is az antitest VL-je a 78. számú szekvenciáiú umino-sav szekvenciát tartalmazza. b Λ/ I vm>y 2. igénypont szerinti rmmekkmaHs antitest, mcly a ί.'04-hez ?xlO"* M-nel ki-vb" '\ értekkel hoiodlk 4. M. L vagy 2. igéstypont 8^ipE«ÄÄii&amp;k sebb l<u értékkel kötődik. V *\«Λ» |Hwu»ïk harme'yik vofmh moookmnahs :«ííík>S ahol az antitest a humán {'pa..| kifejelő humán fák sejtvonalm ('Ok. aktivitással rendelkezik. é> -Mi dóié igénypontok bármelyike szerinti antitestet k‘\1oio DNS. ?. Λ <>· igénypont színűn DRvi tartalmazó rekombináns vektor. 8. Λ ?. Igény pom szerinti rekombináns vektor bevitelével előállítható transziormáns, 0. iΠjárás az í*$. igénypontok bármelyike ezentúl monoktonális antitest előállítására, mélynek áorán u 8. igénypont szerinti transz! omtánst úgy tápközegben tenyészti Ük'az R$<· igénypontok bármelyike s/crinît antitestnek a mpközegben történd termelésére és felhalmozódására, és az; antitestet klnyespk a tény észetöii Uk \/ Ιό. mea> pontok bármelyike szerinti antitest alkalmazása hun un CD4-fOzhiv rákhoz diagnosztikai szer vagy terápiás szer előállítására, lí, hgy lm. igénypontok bármelyike s/etimi amimet CD4-pog||lv rak kezelésében; €04 lzr ífV{> unnumo'og a km utulavtkm \ ,*g> »k'K'wRm. t iU-fxonn κχρ w v;w> klmntalásá-m történő alkalmazásra.
HUE09835062A 2008-12-26 2009-12-25 Anti-CD4 antitest HUE029946T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008331904 2008-12-26

Publications (1)

Publication Number Publication Date
HUE029946T2 true HUE029946T2 (hu) 2017-04-28

Family

ID=42287870

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09835062A HUE029946T2 (hu) 2008-12-26 2009-12-25 Anti-CD4 antitest

Country Status (9)

Country Link
US (2) US8399621B2 (hu)
EP (1) EP2374883B1 (hu)
JP (1) JP5511686B2 (hu)
DK (1) DK2374883T3 (hu)
ES (1) ES2602459T3 (hu)
HU (1) HUE029946T2 (hu)
PL (1) PL2374883T3 (hu)
PT (1) PT2374883T (hu)
WO (1) WO2010074266A1 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
BR112012013734A2 (pt) 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
IL297229A (en) 2012-01-27 2022-12-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
EP3000478A4 (en) 2013-05-23 2017-03-15 IDAC Theranostics, Inc. Therapeutic or prophylactic agent for immunodeficiency virus infection
US10071170B2 (en) * 2013-06-24 2018-09-11 Ablbio Antibody-drug conjugate having improved stability and use thereof
CN105979961B (zh) * 2014-02-05 2020-12-18 西达-赛奈医疗中心 用于治疗癌症和感染性疾病的方法和组合物
EP3338800A1 (en) 2014-02-21 2018-06-27 IDAC Theranostics, Inc. Therapeutic agent for solid cancer
WO2015190538A1 (ja) * 2014-06-11 2015-12-17 Ｉｄａｃセラノスティクス株式会社 免疫チェックポイント制御剤の副作用低減方法
RS62003B1 (sr) * 2014-11-10 2021-07-30 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
JP6274542B2 (ja) * 2014-12-02 2018-02-07 国立大学法人 東京大学 抗ｃｄ４抗体を有効成分とする抗がん剤の治療効果を判定する方法
EP3763731A4 (en) 2018-03-08 2021-11-17 The University of Tokyo PARTIAL PEPTIDE HMGN AND ANTI-CANCER THERAPY USING IT
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
CN114746120A (zh) * 2019-10-03 2022-07-12 Atyr 医药公司 包含抗nrp2抗体的组合物和方法
CN113045661B (zh) * 2021-04-07 2022-06-21 中美冠科生物技术（太仓）有限公司 新型抗cd4抗体
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
CN113831412B (zh) * 2021-10-13 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd24的抗体及其制备和用途
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
JP2564268B2 (ja) 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
US7037496B2 (en) * 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JP3131322B2 (ja) 1991-12-17 2001-01-31 協和醗酵工業株式会社 新規α２→３シアリルトランスフェラーゼ
JP3756946B2 (ja) 1993-03-29 2006-03-22 協和醗酵工業株式会社 α１，３−フコシルトランスフェラーゼ
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
ATE437184T1 (de) 2004-01-12 2009-08-15 Applied Molecular Evolution Varianten der fc-region
SG164379A1 (en) * 2005-07-21 2010-09-29 Genmab As Potency assays for antibody drug substance binding to an fc receptor
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
TWI397536B (zh) * 2005-07-22 2013-06-01 基因重組之抗體組成物

Also Published As

Publication number Publication date
JP5511686B2 (ja) 2014-06-04
EP2374883A4 (en) 2013-01-16
JPWO2010074266A1 (ja) 2012-06-21
US20130177944A1 (en) 2013-07-11
ES2602459T3 (es) 2017-02-21
US20100310573A1 (en) 2010-12-09
PT2374883T (pt) 2016-10-20
US8877913B2 (en) 2014-11-04
US8399621B2 (en) 2013-03-19
PL2374883T3 (pl) 2017-05-31
WO2010074266A1 (ja) 2010-07-01
EP2374883B1 (en) 2016-08-10
EP2374883A1 (en) 2011-10-12
DK2374883T3 (en) 2016-09-26

Similar Documents

Publication Publication Date Title
DK2374883T3 (en) Anti-cd4 antibody
EP2581113B1 (en) Anti-tim-3 antibody
CA2729567C (en) Anti-cd27 antibody
CA2785964C (en) Anti-cd27 antibody
US8076458B2 (en) Anti-claudin-4 antibody
US20120237518A1 (en) Anti-trop-2 antibody
EP2311946B1 (en) Anti-system asc amino acid transporter 2 (asct2) antibody
WO2012074097A1 (ja) 抗ｃｄ３３抗体
JP5812869B2 (ja) 抗システムａｓｃアミノ酸トランスポーター２（ａｓｃｔ２）抗体
WO2013005649A1 (ja) 抗ヒトｃｃｒ６抗体
US10100120B2 (en) Antibody which specifically binds to human CRTH2
US20240026017A1 (en) Anti-human ccr1 monoclonal antibody